Central nervous system (CNS) disorders especially neurodegenerative disorders are the
major challenge for public health and demand the great attention of researchers to protect …

Viral infections are a major global health problem, representing a significant cause of
mortality with an unfavorable continuously amplified socio-economic impact. The increased …

Since the first attempts in the 1970s to isolate cerebral microvessel endothelial cells (CECs)
in order to model the blood–brain barrier (BBB) in vitro, the need for a human BBB model …

In last two decades, the lipid nanocarriers have been extensively investigated for their drug
targeting efficiency towards the critical areas of the human body like CNS, cardiac region …

In recent years, various nanotechnology platforms in the area of medical biology, including
both diagnostics and therapy, have gained remarkable attention. Moreover, research and …

Effective non-invasive treatment of neurological diseases is often limited by the poor access
of therapeutic agents into the central nervous system (CNS). The majority of drugs and …

Although many agents have therapeutic potentials for central nervous system (CNS)
diseases, few of these agents have been clinically used because of the brain barriers. As the …

Effective therapy lies in achieving a therapeutic amount of drug to the proper site in the body
and then maintaining the desired drug concentration for a sufficient time interval to be …

Nanostructured lipid carriers (NLCs) are drug-delivery systems composed of both solid and
liquid lipids as a core matrix. It was shown that NLCs reveal some advantages for drug …

The protective properties of the blood–brain barrier (BBB) are conferred by the intricate
architecture of its endothelium coupled with multiple specific transport systems expressed on …